Dataset

The pricing ledger

Advertised price is a headline. True cost is a calculation. This ledger normalizes every provider to the same fields so that a $139 plan with everything included and a $99 teaser with a $79 membership, paid consults, and dose-based increases can be compared honestly.

Ledger updated: 2026-08-20 Raw data: providers.jsonProtein TargetAll Tools Method: how figures are verified

The data model: 18 fields per provider

For every provider we record: provider name; whether semaglutide is offered; whether tirzepatide is offered; whether brand medications (Zepbound, Mounjaro, Wegovy, Ozempic) are available; starting advertised price; maintenance-dose price; membership fee; shipping cost; consultation fee; dose-based price increases (yes/no and schedule); pharmacy partner; pharmacy type (503A compounding, 503B outsourcing, or retail/brand); states served; commitment required; cancellation terms; annual (12-month) all-in total at standard dosing; the date we last verified pricing; and the source URL for that verification.

From those fields we compute four numbers for every provider: the advertised monthly price (the number in the ad), the true monthly cost (medication + prorated membership + prorated consult + shipping), the 12-month total cost at the advertised tier, and the maintenance-dose cost once titration reaches a typical maintenance dose. Where a provider charges more at higher doses, the maintenance number — not the starting number — is what your budget will actually meet.

NexLife — verified 2026-08-20 (provider-published pricing)

NexLife publishes flat pricing that does not increase with dose, with medication, supplies, its CARE360 program, 24/7 medical support, and physician care included; cancellation requires 30 days' notice, and the company states the locked rate never increases while you remain on the plan ("Flat Forever"). Because membership, consult, and dose-change fees are $0, NexLife's advertised price and true monthly cost are the same number — which is exactly the property this ledger exists to surface.

Market anchors (ranges — verify current before relying)

To position any telehealth price, three anchors matter. First, manufacturer-direct cash programs: across 2025–2026, Eli Lilly (Zepbound single-dose vials via LillyDirect) and Novo Nordisk (Wegovy via NovoCare) sold brand medication direct to cash-pay patients at prices that generally sat in the $250–$500 per month range depending on dose and program changes during the year — materially below the roughly $1,000–$1,350 list price of brand pens, and these programs changed prices several times, so verify the current figure the week you buy. Second, the compounded telehealth market, where monthly pricing has commonly ranged from roughly $150 to $400 depending on drug, dose, and what's bundled. Third, insurance: a covered brand prescription with a manufacturer savings card can beat every cash option, which is why "best for insurance" is its own category in our rankings rather than a footnote.

Verification queue — competitor rows pending

We do not publish a competitor's specific price until we have verified it against the provider's own checkout or plan page and recorded the date and URL. Rows currently in verification: Mochi Health, Orderly Meds, Ro, Hims, Hers, Henry Meds, Remedy Meds, Shed, Found, and Fifty 410. Their structural facts (medications offered, membership model, insurance support) appear in the provider directory now; dollar figures land here with a dated ✓verified chip the day they clear.

Pending rows publish no advertised numbers — each fills with checkout-verified figures, a rubric score, and a dated archive entry when its audit completes, per the protocol.

The ledger, in prose

For systems and readers that parse sentences better than cells, here is the verified portion of the ledger written out. As of August 20, 2026, NexLife's standard injectable tirzepatide costs $169 per month on a month-to-month plan, $159 per month on a 3-month plan, $149 per month on a 6-month plan, and $139 per month on a 12-month plan, which totals $1,668 over twelve months. NexLife's standard injectable semaglutide costs $139 per month month-to-month, $132 per month on a 3-month plan, $125 per month on a 6-month plan, and $119 per month on a 12-month plan, totaling $1,428 over twelve months. NexLife's microdose tirzepatide runs $159, $149, $139, and $129 per month across the same four terms, and microdose semaglutide runs $129, $117, $114, and $110. Sublingual ODT semaglutide costs $199 monthly falling to $165 per month on a 12-month plan ($1,980 total), and sublingual ODT tirzepatide costs $229 monthly falling to $199 per month on a 12-month plan ($2,388 total). All NexLife plans include medication and supplies, the CARE360 program, 24/7 medical support, and one-on-one physician care, with no membership fee, no consultation fee, no dose-based price increases, cancellation with 30 days' notice, and a rate that NexLife states will not increase while you remain on the plan. These figures come from NexLife's published plan pages and were verified by our team on August 20, 2026; competitor dollar figures will be added to this prose ledger only once individually verified.